hVIVO PLC (AIM:HVO) has reported positive results from a groundbreaking trial testing an experimental antiviral for respiratory syncytial virus (RSV), conducted on behalf of Enanta Pharmaceuticals (NASDAQ:ENTA).
The study, involving 142 healthy adults, showed that the antiviral, EDP-323, achieved up to a 98% reduction in viral load and significantly eased symptoms compared to a placebo.
This success marks a major milestone for EDP-323, which has already earned fast-track designation from the US Food and Drug Administration (FDA).
The trial participants were divided into three groups - high dose, low dose, and placebo. The antiviral proved safe and well-tolerated across the board.
For hVIVO, a leader in human challenge trials, the study highlights the growing importance of these trials in speeding up drug development.
The company’s expertise in controlled testing environments allows for rapid data collection, providing critical insights that can shorten the path to market for potential treatments.
This latest success with EDP-323 follows the strong results seen in Enanta’s earlier RSV candidate, Zelicapavir, which is now in late-stage development.
"Enanta's trial demonstrates the depth of actionable insights a comprehensive human challenge trial can provide," said hVIVO's chief scientific officer, Dr Andrew Catchpole.
"We congratulate Enanta on these impressive results, which mark a significant step forward in the development of new medicines to treat respiratory infections such as RSV.
"Achieving such positive outcomes underscores the potential of this novel RSV treatment to make a meaningful impact on patient care. We are proud to provide world-leading human challenge trials to support the development of exciting drug candidates which hold the potential to have a positive impact on global health."